Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.73 |
| ▸ | PKM | P14618 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | TSHR | P16473 | 2/20 | 0.70 |
| ▸ | HTT | P42858 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29910129 | 1.00 | L3MBTL1 (0.97) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL335214 | 0.99 | L3MBTL1 (0.95) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL2624464 | 0.87 | L3MBTL1 (0.76) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL334535 | 0.86 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL334642 | 0.86 | L3MBTL1 (0.74) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL334483 | 0.81 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL11619459 | 0.80 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| SCHEMBL11619637 | 0.80 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| Hydrochloric Acid SCHEMBL11619986 | 0.79 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1MEN1KMT2APKM | |
| Hydrochloric Acid SCHEMBL11624462 | 0.79 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1MEN1KMT2APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1985620-A1 | 10a-AZALIDE COMPOUND | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | L3MBTL1 2853/4885ALDH1A1 1939/4885MEN1 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.